Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-10-26

Clinical Trial Update: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines [Phase 3]

View source ↗

Summary

Phase 3 trial comparing incobotulinumtoxinA (Xeomin) to placebo for the treatment of glabellar frown lines has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: Merz Pharmaceuticals GmbH | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED